A small-molecule TRPV4 inhibitor (GSK2193874) was tested in bleomycin lung fibrosis models and found to reduce lung inflammation and fibrosis by blocking TRPV4–mediated Ca2+ influx in fibroblasts, which is necessary for the TRPV4–PI3Kγ scaffold function. Here, TRPV4 is linked to pulmonary fibrosis.